Drug intelligence / Profile preview

Cerenx

Development stage: Unknown
Lead developer: DIEM Labs
Modality: Small Molecules
Administration: Oral

Overview

Cerenx is an oral medical food product developed by Diem Labs for the distinct nutritional needs of people experiencing age-related cognitive decline and related memory concerns. Its active ingredient is sodium citicoline, a small-molecule form of citicoline also known as CDP-choline, supplied as 500 mg per product unit. Citicoline is a precursor for phosphatidylcholine and acetylcholine biosynthesis and is intended to support neuronal membrane metabolism and cholinergic neurotransmitter production rather than act as a conventional pharmaceutical drug. Based on the provided context, Cerenx is positioned in the United States as a medical food rather than a dietary supplement or approved pharmaceutical.

Brand names: Cerenx
Other names: sodium citicolineciticolineCDP-choline

Beyond the preview

Go deeper on Cerenx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerenx.

Explore the full profile